AU2001242965A1 - Method of inhibiting the expression of inflammatory cytokines and chemokines - Google Patents
Method of inhibiting the expression of inflammatory cytokines and chemokinesInfo
- Publication number
- AU2001242965A1 AU2001242965A1 AU2001242965A AU4296501A AU2001242965A1 AU 2001242965 A1 AU2001242965 A1 AU 2001242965A1 AU 2001242965 A AU2001242965 A AU 2001242965A AU 4296501 A AU4296501 A AU 4296501A AU 2001242965 A1 AU2001242965 A1 AU 2001242965A1
- Authority
- AU
- Australia
- Prior art keywords
- chemokines
- expression
- inflammatory cytokines
- man
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000019034 Chemokines Human genes 0.000 title abstract 5
- 108010012236 Chemokines Proteins 0.000 title abstract 5
- 102000004127 Cytokines Human genes 0.000 title abstract 5
- 108090000695 Cytokines Proteins 0.000 title abstract 5
- 230000002757 inflammatory effect Effects 0.000 title abstract 5
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 abstract 3
- 235000013793 astaxanthin Nutrition 0.000 abstract 3
- -1 astaxanthin Chemical compound 0.000 abstract 3
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 abstract 3
- 229940022405 astaxanthin Drugs 0.000 abstract 3
- 239000001168 astaxanthin Substances 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 abstract 3
- 229960005375 lutein Drugs 0.000 abstract 3
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 abstract 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 abstract 3
- 235000008210 xanthophylls Nutrition 0.000 abstract 3
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0001071 | 2000-03-27 | ||
| SE0001071A SE0001071D0 (sv) | 2000-03-27 | 2000-03-27 | Method of inhibiting the expression of inflammatory cytokines and chemokines |
| PCT/SE2001/000600 WO2001072296A1 (en) | 2000-03-27 | 2001-03-21 | Method of inhibiting the expression of inflammatory cytokines and chemokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001242965A1 true AU2001242965A1 (en) | 2001-10-08 |
Family
ID=20279020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001242965A Abandoned AU2001242965A1 (en) | 2000-03-27 | 2001-03-21 | Method of inhibiting the expression of inflammatory cytokines and chemokines |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1267857B1 (https=) |
| JP (1) | JP2003528139A (https=) |
| AT (1) | ATE353639T1 (https=) |
| AU (1) | AU2001242965A1 (https=) |
| CA (1) | CA2405479C (https=) |
| DE (1) | DE60126591D1 (https=) |
| SE (1) | SE0001071D0 (https=) |
| WO (1) | WO2001072296A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002349784A1 (en) * | 2001-12-03 | 2003-06-17 | Asahi Kasei Pharma Corporation | Nf-kappab activating genes |
| EP2653157B1 (en) | 2004-02-04 | 2016-08-03 | Fuji Chemical Industry Co., Ltd. | Astaxanthin for improving muscle atrophy |
| JP2006008714A (ja) * | 2005-03-17 | 2006-01-12 | Yamaha Motor Co Ltd | マトリックスメタロプロテイナーゼ阻害剤 |
| JP2006008718A (ja) * | 2005-06-03 | 2006-01-12 | Yamaha Motor Co Ltd | シクロオキシゲナーゼ活性阻害剤 |
| JP2006008719A (ja) * | 2005-06-23 | 2006-01-12 | Yamaha Motor Co Ltd | 血中過酸化脂質抑制剤 |
| US7805004B2 (en) * | 2007-02-28 | 2010-09-28 | Microsoft Corporation | Radical set determination for HMM based east asian character recognition |
| WO2008106606A2 (en) * | 2007-02-28 | 2008-09-04 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs and derivatives in the treatment of prostate cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05155736A (ja) * | 1991-12-10 | 1993-06-22 | Nakano Seiyaku Kk | 化粧料 |
| JPH0799924A (ja) * | 1993-09-30 | 1995-04-18 | Nippon Suisan Kaisha Ltd | アスタキサンチンを主要成分とするファフィア色素油の安定な粉末化物及びその製造方法 |
| JPH07300421A (ja) * | 1994-04-28 | 1995-11-14 | Itano Reitou Kk | 抗炎症剤 |
| US5527533A (en) * | 1994-10-27 | 1996-06-18 | Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
| WO1996023489A2 (de) * | 1995-02-03 | 1996-08-08 | Basf Aktiengesellschaft | Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen |
| JPH09124470A (ja) * | 1995-10-26 | 1997-05-13 | Suntory Ltd | 抗ストレス組成物 |
| JPH09143063A (ja) * | 1995-11-22 | 1997-06-03 | Kose Corp | 外用に適する組成物 |
| SE522246C2 (sv) * | 1997-02-27 | 2004-01-27 | Astacarotene Ab | Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion |
| JP2002513411A (ja) * | 1997-04-04 | 2002-05-08 | ヘンケル コーポレーション | 高いバイオアベイラビリティを有するルテインエステル |
| SE512531C2 (sv) * | 1997-09-04 | 2000-03-27 | Astacarotene Ab | Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur |
-
2000
- 2000-03-27 SE SE0001071A patent/SE0001071D0/xx unknown
-
2001
- 2001-03-21 WO PCT/SE2001/000600 patent/WO2001072296A1/en not_active Ceased
- 2001-03-21 AT AT01916022T patent/ATE353639T1/de not_active IP Right Cessation
- 2001-03-21 CA CA2405479A patent/CA2405479C/en not_active Expired - Fee Related
- 2001-03-21 AU AU2001242965A patent/AU2001242965A1/en not_active Abandoned
- 2001-03-21 EP EP01916022A patent/EP1267857B1/en not_active Expired - Lifetime
- 2001-03-21 DE DE60126591T patent/DE60126591D1/de not_active Expired - Fee Related
- 2001-03-21 JP JP2001570257A patent/JP2003528139A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1267857A1 (en) | 2003-01-02 |
| CA2405479C (en) | 2010-11-16 |
| CA2405479A1 (en) | 2001-10-04 |
| SE0001071D0 (sv) | 2000-03-27 |
| ATE353639T1 (de) | 2007-03-15 |
| WO2001072296A1 (en) | 2001-10-04 |
| JP2003528139A (ja) | 2003-09-24 |
| EP1267857B1 (en) | 2007-02-14 |
| DE60126591D1 (de) | 2007-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU57600A (sh) | Derivarti biciklične hidroksaminske kiseline | |
| EP1137403A4 (en) | A HYDROCOLLOID AND A DELIVERY-RELATED TABLET CONTAINING CELLULOSE ETHER | |
| MY111791A (en) | Aqueous gel retinoid dosage form. | |
| NZ516347A (en) | Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them | |
| WO2002053101A3 (en) | Method for treating fibrotic diseases or other indications | |
| MXPA04004601A (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. | |
| WO2002069945A3 (de) | Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren | |
| AU2084801A (en) | Antiviral medication | |
| MX9800408A (es) | Sales de derivados de amidina y de inhibidor de ciclooxigenasa, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen. | |
| EP1167354A3 (en) | Racemic huperzine A | |
| SE9802208D0 (sv) | Novel compounds | |
| AU1705392A (en) | Substituted diaminophthalimides and analogues | |
| WO1987007835A1 (fr) | Medicament pour le traitement et la prophylaxie de maladies du rein et du foie | |
| AU2001242965A1 (en) | Method of inhibiting the expression of inflammatory cytokines and chemokines | |
| ES2174113T3 (es) | Nuevos derivados de ((3-alcoxi-fenoxi)-etil)-dialquilamina y su utilizacion como anestesicos locales. | |
| AU5634500A (en) | Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis | |
| PH27446A (en) | Compound with gastric acid inhibitory effect | |
| AU2002223970A1 (en) | Kyberdrug as autovaccines with immune-regulating effects | |
| WO2002022107A3 (en) | Pharmaceutical composition having modified carrier | |
| HK1045987A1 (zh) | 3-氨基-2-苄基-1-苯基-丙烷衍生物 | |
| GEP20043231B (en) | Resorcinol Composition | |
| AU4929400A (en) | Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof | |
| JP2003528139A5 (https=) | ||
| AU2811400A (en) | Stable formulation containing fumagillin | |
| AU3903701A (en) | Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase |